Given the lower growth forecast, analysts express concern that should the P/E fall in line with the growth outlook, share price might decline. Investors currently holding onto their stock could face future disappointment.
Issuing new shares has diluted EPS growth, potentially affecting the stocks appeal to investors. Despite improved profits, slower EPS growth due to dilution is worrying. Future company profitability estimates are key.
The market tempers expectations for IDACORP growth despite consistent EPS growth. Warning signs surface in IDACORP's investment analysis. Though its strategy attracted investors thanks to better 5yr returns.
Upgrades •$Agora (API.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $12.50 •$argenx SE (ARGX.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $375 (from $278) •$Idacorp (IDA.US)$: Wells Fargo Upgrades to Equal Weight from Underweight - PT $110 (from $108) •$Jakks Pacific (JAKK.US)$: BMO Capital Upgrades to Outperform from Market Perform - PT $21 •$Coca-Cola FEMSA (KOF.US)$: Barclays Upgrades to Overweight from Equal Wei...
Idacorp Stock Forum
• $Agora (API.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $12.50
• $argenx SE (ARGX.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $375 (from $278)
• $Idacorp (IDA.US)$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $110 (from $108)
• $Jakks Pacific (JAKK.US)$ : BMO Capital Upgrades to Outperform from Market Perform - PT $21
• $Coca-Cola FEMSA (KOF.US)$ : Barclays Upgrades to Overweight from Equal Wei...
No comment yet